Phase 3 data show Dupixent improves signs and symptoms of prurigo nodularis
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
This drive will expand access to quality diagnostics and help find the ‘missing millions’ – patients that are suffering from TB but not registered in the healthcare system
A staggering 65% of the TB cases in India are in the 15-45 age group
The next-gen logistics management solutions are making the global supply chains more customer-centric and sustainable
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India
Subscribe To Our Newsletter & Stay Updated